At present, a number of EGFR-TKIs, including erlotinib, gefitinib, afatinib, and osimertinib, are available and are being actively employed in clinical practice to treat NSCLC, with a particular focus on targeting EGFR mutations [23]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.